Omecamtiv Mecarbil Safe in Healthy Chinese Participants
A phase I clinical trial has confirmed that omecamtiv mecarbil, a cardiac myosin activator, is safe and well tolerated in...
Ophelia Keating is a Scienmag editorial specialist profile for Health Services Research coverage.
A phase I clinical trial has confirmed that omecamtiv mecarbil, a cardiac myosin activator, is safe and well tolerated in...
The inaugural 2025 Cardiometabolic Summit, held in Saclay, France, convened 110 clinicians from Algeria, Morocco, and Tunisia to address the...
A retrospective study published in Acta Neurochirurgica reports that neighborhood socioeconomic status, insurance coverage, and race are associated with tumor...
A narrative review proposes combining clinical phenotypes with early hemodynamic assessment to guide targeted angiotensin II therapy in vasodilatory shock.
A comprehensive narrative review demonstrates how integrating temporal dimensions into postmortem imaging enhances forensic reconstructions of injury mechanisms and biological...
A Swedish cohort study demonstrates that echocardiographic left atrial and ventricular strain metrics offer independent prognostic insight into mortality and...
An anchored matching-adjusted indirect comparison indicates tralokinumab achieved higher rates of deep skin clearance and greater daily activity improvement than...
In older emergency patients with sepsis, SOFA-2 demonstrated good short-term mortality discrimination but did not improve prognostic performance over the...
A case–control study finds that patients with temporal lobe epilepsy exhibit autonomic dysregulation and elevated frontal theta power correlated with...
A cross-sectional study at Muni University in Uganda found that HIV self-testing uptake among students and staff is associated with...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine